Osaka, Japan (Feb-18) Takeda Pharmaceutical Company Limited “Takeda” today announced that the investigational compound, Hematide™, of which Takeda and Affymax Inc (Palo Alto, Calif) “Affymax” contracted the global license agreement, for the treatment of anemia in chronic renal failure has entered into phase 3 clinical program in Japan.
http://digg.com/u1NeW4
No comments:
Post a Comment